Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Scientific Reports|December 26, 2019
Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancerNicholas Willumsen, Suhail M Ali, Kim Leitzel, et al.
Breast Cancer Research and Treatment|May 10, 2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)Diep Ho, Jessica Huang, Judith-Anne W Chapman, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesAllan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Calcified Tissue International|June 20, 2018
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone MetastasisEvelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyAllan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2015
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Henry G Bone, Richard H de Boer, et al.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Scientific Reports|December 26, 2019
Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancerNicholas Willumsen, Suhail M Ali, Kim Leitzel, et al.
Breast Cancer Research and Treatment|May 10, 2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)Diep Ho, Jessica Huang, Judith-Anne W Chapman, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesAllan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Calcified Tissue International|June 20, 2018
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone MetastasisEvelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyAllan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2015
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Henry G Bone, Richard H de Boer, et al.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Pageof 15